Company intelligence / Profile preview
Evec
Sapporo, Hokkaido, Japanevec.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Evec has developed and demonstrated the ability to generate fully human monoclonal antibodies against multiple infectious agents, including SARS-CoV-2 (COVID-19), Clostridium difficile, cytomegalovirus, herpes simplex virus, and metapneumovirus, with reported neutralizing activity; products are available for licensing and contract services
- Therapeutic areas
- OncologyInfectious DiseasesImmunology
- Modalities
- Monoclonal antibodyRecombinant protein
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Collaboration with multiple Japanese hospitals and research institutes for COVID-19 programLicensed monoclonal antibody to large foreign pharmaceutical company in 2008Yamaha Motor is an investor
Beyond the preview
Go deeper on Evec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evec.